SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Anticipation of Teslas Cybercab launch, reinforced by pedal-less vehicles being added to Texass robotaxi roster, is driving attention to TSLA. Traders are divided between optimism over robotaxi/FSD expansion and expectations of a short squeeze, and skepticism that the event is largely hype that could trigger a sell-the-news pullback.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Anticipation of Vikings VK2735 maintenance-trial readout is driving attention, with traders focused on durable weight loss, efficacy, and tolerability as key validation for the obesity program. Bullish participants expect differentiated results to support a re-rating or potential partnership, while bearish traders question whether the data will exceed existing GLP-1 therapies and warn of sell-the-news pressure and dilution.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

JEPQ is drawing attention around its monthly distribution announcement and payout, with traders celebrating the elevated income and discussing reinvestment strategies. The community is also debating whether the distribution is sustainable and noting that Nasdaq-linked volatility can support option premiums while limiting upside and pressuring the share price after the ex-dividend date.

Edison International is a renewable energy company, which operates through its subsidiaries. It supplies and distributes electric power, and also invests in energy services and technologies. The company was founded on July 4, 1886, and is headquartered in Rosemead, CA.

Edison International

California lawmakers failure to include expected protections against wildfire-related claims has intensified concerns over Edison Internationals liability exposure, prompting analyst downgrades and a sharp selloff. Traders are divided between bears warning of prolonged legal, credit and dividend risk and bulls calling the decline an overreaction and buying the oversold dip.

Corvex, Inc. is an AI cloud computing company, which specializes in GPU-accelerated infrastructure for AI workloads. Its products include GPU Clusters, Confidential Computing, Inference as a Service and GPU Node. The firm offers solutions include AI model builders, enterprises, federal and sovereign solutions. The company was founded by Seth Mitchell Demsey, Jay Crystal on October 21, 2024 and is headquartered in Arlington, VA.

Corvex Inc.

Movano Inc

A multi-year agreement for Corvex to provide NVIDIA Blackwell GPU clusters to an AI company, alongside planned data-center expansion, is driving attention and repositioning MOVE around an AI-infrastructure story. Traders are split between bullish expectations for momentum and a low-float short squeeze and concerns about the discounted financing, dilution risk, execution, and sharp post-pump fades.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

A broad Bitcoin-led crypto rally is driving attention to Coinbase as a high-beta proxy, with traders citing renewed momentum, a technical breakout, and potential short covering. Bullish participants expect the move to continue, while skeptics call it speculative and note that Coinbase has lagged Bitcoin and remains sensitive to interest-rate concerns.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Attention is centered on Keeta Personals rollout of ACH and multicurrency payment features alongside its Visa Direct partnership, which traders view as a potential fiat-to-blockchain payments catalyst. The community is broadly bullish, though skeptics question whether Visa is using Keetas network and whether meaningful transaction volume will follow, with the ASK Group UAE tokenization venture adding longer-term context.

Daily surprises, near and far. Your source for travel inspiration and more. Travel moves you!

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

The dominant catalyst is uncertainty over Paramount Skydances proposed acquisition of Warner Bros. Discovery after Californias attorney general canceled settlement talks amid the multistate antitrust case. Traders remain divided between expectations of a negotiated resolution and concerns that prolonged litigation could delay or derail the merger, increasing downside risk for WBD holders.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

A recent quarterly report showing minimal revenue growth and declining policies-in-force has focused attention on Roots stalled growth strategy. Bulls emphasize continued profitability, cash generation, and the share-buyback program, while bears argue that reduced marketing spending supported earnings at the expense of customer growth and leaves the stock vulnerable to further weakness.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is drawing attention as it consolidates near a major resistance area, with traders debating whether buyers can sustain a breakout or whether macro pressure from elevated yields, potential rate hikes, and seasonal weakness will trigger another pullback. The community remains sharply divided between bullish accumulation and breakout expectations and bearish warnings of rejection and deeper declines.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.

Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of +90.00% and +6.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotechnology Reports Second Quarter 2026 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2026. Unless otherwise stated, all comparisons are for the second quarter 2026 compared to the second quarter 2025. Product revenue, net consists entirely of...

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 3, 2026, the Compensation Committee of Pumas Board of Directors approved the grant of inducement restricted stock unit awards covering 35,375 shares of Puma common stock to five new non-executive...

Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, August 6, 2026, following the release of its second quarter 2026 financial results.The call may be accessed by dialing 1-877-709-8150 (domestic) or...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2026, the Compensation Committee of Pumas Board of Directors approved the grant of inducement restricted stock unit awards covering 31,625 shares of Puma common stock to four new non-executive employees...

Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why

PBYI's shares rally 19% in three months as rising Nerlynx demand and a raised 2026 revenue outlook boost investor confidence.

• Reported GAAP EPS of $0.16 up 33.33% YoY
• Reported revenue of $56.5M up 7.75% YoY
• Puma Biotechnology raised its full year 2026 guidance, now anticipating net product revenue of $205-$209 million, total revenue of $224-$231 million, and net income in the range of $17-$20 million.

Puma Biotechnology experienced a significant decline in quarterly operating cash flow and higher research and development expenses, alongside inherent structural risks related to clinical trial outcomes and regulatory approval processes.

Puma Biotechnology demonstrated growth in NERLYNX product revenue and improved GAAP net income, while strengthening its balance sheet by successfully eliminating all outstanding debt during the second quarter of 2026.

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Puma Biotechnology Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$0.09	--	--	N/A
Q2 '26	$0.04	$0.16	300.00%	BEAT
Q1 '26	-$0.17	-$0.07	58.82%	BEAT
Q4 '25	$0.19	$0.26	36.84%	BEAT
Q3 '25	$0.05	$0.17	277.78%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings